✦ LIBER ✦

Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer

✍ Scribed by Kimberly K. Leslie; Michael W. Sill; Heather A. Lankes; Edgar G. Fischer; Andrew K. Godwin; Heidi Gray; Russell J. Schilder; Joan L. Walker; Krishnansu Tewari; Parviz Hanjani; Ovadia Abulafia; Peter G. Rose

Book ID: 118506822
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 723 KB
Volume: 127
Category: Article
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2012.07.127

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of danazol in advanced, r

Phase II trial of danazol in advanced, recurrent, or persistent endometrial cancer: a Gynecologic Oncology Group study

✍ Allan Covens; Virginia L Brunetto; Maurie Markman; James W Orr Jr.; Samuel S Len 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 72 KB

A Phase II Trial of Anastrozole in Advan

A Phase II Trial of Anastrozole in Advanced Recurrent or Persistent Endometrial Carcinoma: A Gynecologic Oncology Group Study

✍ Peter G. Rose; Virginia L. Brunetto; Linda VanLe; Jeffrey Bell; Joan L. Walker; 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 45 KB

Phase II Trial of Pyrazoloacridine in Pa

Phase II Trial of Pyrazoloacridine in Patients with Persistent or Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study

✍ Steven C. Plaxe; John A. Blessing; Nader Husseinzadeh; Kenneth D. Webster; Janet 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 39 KB

A Phase II Trial of Topotecan in Patient

A Phase II Trial of Topotecan in Patients with Advanced, Persistent, or Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study

✍ David Scott Miller; John A. Blessing; Samuel S. Lentz; Steven E. Waggoner 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 41 KB

Predictive and prognostic angiogenic mar

Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer

✍ Ernest S. Han; Robert A. Burger; Kathleen M. Darcy; Michael W. Sill; Leslie M. R 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 415 KB

A phase II evaluation of aflibercept in

A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study

✍ Robert L. Coleman; Michael W. Sill; Heather A. Lankes; Amanda Nickles Fader; Nei 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 246 KB